Investors brush off Car-T scare
But the FDA’s investigation looks like worse news for autoimmune disease than oncology.
A reprieve for Blenrep?
Against the odds GSK’s Dreamm-7 study yields a positive survival readout.
Gilead ups its bet on Arcellx and BCMA
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
Cell therapy groups double down on speedy manufacturing
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
AbbVie opt-out puts the focus on TeneoOne
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
